Medicus Pharma submits Type C meeting request to FDA to advance skin cancer treatment

Medicus Pharma (NASDAQ:MDCX) has submitted a Type C meeting request to the FDA to discuss the clinical development pathway for its dissolvable doxorubicin-containing microneedle array (D-MNA) product targeting basal cell carcinoma, aiming for potential fast-track designation. This move follows positive interim results from its ongoing Phase 2 study (SKNJCT-003), which reported over 60% clinical clearance. The company seeks FDA feedback on dosing, study design, and clinical endpoints, with its shares rising 5% on the news, reflecting investor optimism regarding regulatory progress and clinical potential.

Analysis

Medicus Pharma (NASDAQ:MDCX) has taken a significant step to advance its dissolvable doxorubicin-containing microneedle array (D-MNA) for basal cell carcinoma by formally requesting a Type C meeting with the FDA. This strategic move, aimed at securing an expedited development pathway, is supported by a compelling clinical data history. The ongoing Phase 2 study (SKNJCT-003) showed promising interim results in March 2025, with over 60% clinical clearance among randomized patients, justifying the trial's expansion. This builds on a successful Phase 1 study (SKNJCT-001) that not only met its safety and tolerability objectives but also demonstrated early efficacy, with 6 of 13 participants showing a complete histological response. The company is proactively seeking FDA guidance on critical trial design elements, including the use of complete histological clearance as a primary endpoint. The market's positive reception, reflected in a 5% share price increase to approximately $3.60, underscores investor confidence in the regulatory progress and the potential of the D-MNA platform.

Key Decisions for Investors

• Investors should view the upcoming Type C meeting with the FDA, targeted for the week of October 6th, as the next major catalyst for Medicus Pharma, as a favorable outcome on the clinical pathway or fast-track designation could significantly de-risk the asset.
• Monitor for complete data from the ongoing Phase 2 (SKNJCT-003) trial, as the final results will need to validate the strong interim signal of over 60% clinical clearance to maintain fundamental support for the valuation.
• Given the positive clinical and regulatory momentum, existing shareholders might consider holding their positions into the catalyst, while prospective investors should weigh the potential upside against the binary risk associated with the forthcoming FDA feedback.